# 1 **Article title:** Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies

- 2 novel clusters and divergent ex-vivo drug responses
- 3
- 4 Jeppe F Severens<sup>1,2,3</sup>, E Onur Karakaslar<sup>1,2,3</sup>, Bert A van der Reijden<sup>4</sup>, Elena Sánchez-López<sup>3,5</sup>, Redmar
- 5 R van den Berg<sup>6</sup>, Constantijn JM Halkes<sup>7</sup>, Peter van Balen<sup>7</sup>, Hendrik Veelken<sup>3,7</sup>, Marcel JT Reinders<sup>1,2,3</sup>,
- 6 Marieke Griffioen<sup>7</sup>, Erik B van den Akker<sup>1,2,3</sup>
- 7
- 8 <sup>1</sup>Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- 9 <sup>2</sup>Pattern Recognition & Bioinformatics, Delft University of Technology, Delft, The Netherlands
- 10 <sup>3</sup> Leiden Center for Computational Oncology, Leiden University Medical Center, Leiden, The Netherlands
- 11 <sup>4</sup> Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center,
- 12 Nijmegen, The Netherlands
- 13 <sup>5</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
- 14 <sup>6</sup>Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
- 15 7Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
- 16

# 17 **Corresponding author:**

- 18 Erik B. van den Akker, PhD; Department of Biomedical Data Sciences, Leiden University Medical Center,
- 19 Leiden, The Netherlands; Einthovenweg 20, 2333 ZC, Leiden, The Netherlands; Tel: +31 (0)71 526 85
- 20 57; Fax: +31 (0)71 526 82 80; E-mail: [e.b.van\\_den\\_akker@lumc.nl](mailto:e.b.van_den_akker@lumc.nl)
- 21

# 22 **Disclosure of interest**

- 23 The authors declare no competing financial interests.
- 24
- 25

# **Abstract**

 Subtyping of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic abnormalities, but recent literature indicates that transcriptomic phenotyping holds immense potential to further refine AML classification. Here we integrated five AML transcriptomic datasets with corresponding genetic information to provide an overview (n=1224) of the transcriptomic AML landscape. Consensus clustering identified 17 robust patient clusters which improved identification of *CEBPA*-mutated patients with favourable outcomes, and uncovered transcriptomic subtypes for *KMT2A* rearrangements (2), *NPM1* mutations (5), and AML with myelodysplasia-related changes (AML-MRC) (5). Transcriptomic subtypes of *KMT2A*, *NPM1* and AML-MRC showed distinct mutational profiles, cell type differentiation arrests and immune properties, suggesting differences in underlying disease biology. Moreover, our transcriptomic clusters show differences in ex-vivo drug responses, even when corrected for differentiation arrest and superiorly capture differences in drug response compared to genetic classification. In conclusion, our findings underscore the importance of transcriptomics in AML subtyping and offer a basis for future research and personalised treatment strategies. Our transcriptomic compendium is publicly available and we supply an R package to project clusters to new transcriptomic studies.

# **Introduction**

 In acute myeloid leukaemia (AML), recurrent genetic abnormalities (RGA) have been identified 43 through systematic genomic studies.<sup>1-5</sup> Based on these RGAs, the World Health Organization (WHO 2022) and International Consensus Classification (ICC 2022) define several AML subtypes, as well as a 45 heterogeneous subtype of AML with myelodysplasia-related changes (AML-MRC).<sup>6,7</sup> RGAs are essential for risk-stratification and are increasingly targeted with drugs.<sup>8,9</sup>

 AML subclassification is genetics-based, but transcriptomics holds immense potential to refine 48 AML classification further.<sup>1-3,10-12</sup> Transcriptomic studies have led to the discovery of *CEBPA*-mutated 49 AML<sup>13,14</sup>, and *NPM1*-mutated AML subtypes with different cell differentiation arrests and ex-vivo drug 50 responses.<sup>15,16</sup> Similar stratification would be beneficial for AML-MRC, given its heterogeneity.<sup>17,18</sup> Still, a comprehensive examination of AML subtypes defined by gene expression has yet to be performed. 52 Furthermore, the differentiation arrest state is known to modify drug response in AML<sup>19</sup>, and failing to account for this effect when comparing drug responses could skew conclusions.

 Therefore, we integrated five mRNAseq datasets with corresponding genetic aberration data and annotated cases according to WHO and ICC 2022 standards. We outline AML's transcriptomic landscape and define transcriptional subtypes with distinct gene expressions, genetic aberrations, and cell type arrests. We relate the clusters to ex-vivo drug responses independently of differentiation arrest and show how they superiorly capture differences in response compared to genetic classification. We provide all harmonised data and a transcriptional cluster predictor for future research. Our study underscores the importance of incorporating transcriptomic data in AML classification.

#### **Methods**

#### **Transcriptomic data**

 We acquired transcriptomics data of primary AML patients from blood or bone marrow from 66 BEAT<sup>3,20</sup> (n = 425), TARGET<sup>2</sup> (n = 145), TCGA<sup>1</sup> (n = 150), and Leucegene<sup>11,21–23</sup> (n = 399), and our in-67 house LUMC<sup>24</sup> dataset (n = 95). Data statements and methods for transcriptome sequencing are available in the referenced studies.

 We acquired quantified gene expression for BEAT, TARGET and TCGA from https://portal.gdc.cancer.gov/ (release 36) and implemented the same pipeline for Leucegene and LUMC 71 to harmonise quantification. In short, FASTQ files were aligned and quantified with  $STAR^{25}$  to the GRCh38 reference genome<sup>26</sup>, using Gencode v36<sup>27</sup> as the gene annotation index which included 60600 genes.

74 Gene expression count data were corrected with Combat-Seq<sup>28</sup> for the variables "cohort", "sex", and "tissue". We split Leucegene for the batch correction into Leucegene\_stranded and Leucegene\_unstranded, since different sequencing libraries were used. We removed 8057 genes that were not detected in all cohorts, leaving 52603 genes. Finally, we removed genes detected in less than 200 samples or with less than 300 counts leaving 41862 genes for our final dataset. We normalised the 79 corrected count data using the geometric mean and variance stabilising transformation (VST) $^{29}$  and quantified the remaining cohort-specific variation using kBET.<sup>30</sup>

### **Genetic and patient data**

 We acquired genetic data for the samples from the referenced studies in the form of mutation and fusion calling, and cytogenetics data and clinical data on sex, age, blast percentage, and survival. 85 Blacklisted fusions as reported by Arriba<sup>31</sup> were removed from the fusion calling data.

 We harmonised the data by standardising the annotation of gene names, fusion genes, and 87 karyotyping. Using genetic data, we subclassified samples according to the WHO 2022<sup>6</sup> and ICC 2022<sup>7</sup>. Samples for which we found no RGA and all genetic data available were annotated as "No RGA found".

We classified samples with missing data and "No RGA found" as "Inconclusive".

**Clustering**

 We employed consensus clustering<sup>32,33</sup> on the batch-adjusted gene expression. First, we created 93 a weighted nearest neighbour graph<sup>34</sup> using the 2000 most variable genes (MVGs). MVGs were selected via the median absolute deviation from samples with a blast percentage over 70% to minimise tumour 95 microenvironment effects. Using the Leiden algorithm<sup>35</sup> – with seed and resolution varied per iteration – we generated 300 cluster assignments from the graph for each n\_clusters ranging from 10 to 20, totaling 3300 assignments.

 From these 3300 assignments we created a consensus matrix with values ranging between 0 and 1 based on pairwise co-clustering. We then converted this matrix into a distance matrix (1 - consensus matrix) and conducted Ward.D2 hierarchical clustering. The final cluster count was determined based on the individual separation of WHO classes and clusters displaying differential traits.

#### **Cluster stability**

 To evaluate per sample clustering stability, we devised a stability score. We constructed a consensus matrix for each n\_clusters (300 assignments) and subtracted each co-clustering value from 1 if it was below 0.5. Then, we took the mean of all values per sample as the stability score, which ranged from 0.5 to 1, with higher scores indicating less clustering ambiguity. To investigate correlation between cluster stability and blast percentage we performed a Spearman correlation test. Additionally, we generated tSNEs using 100 to 2500 MVGs to visually assess cluster stability.

#### **Cluster prediction**

 To predict cluster assignments we trained a one-vs-rest SVM per cluster. As input we used the uncorrected gene expression of the 2000 MVGs used for clustering. To select hyperparameters and evaluate performance we utilised 5x5 nested cross-fold validation.

 To improve predictions we included a reject option using a minimum distance to the decision boundary. We determined this distance by looping over possible minimum values for the predictions of the inner fold. We selected the minimum value with the highest Kappa for the accepted inner fold samples and an accuracy < 0.5 for the rejected inner folds samples.

 The final model was trained on the whole dataset, using 5-fold cross-validation to select hyperparameters and the minimum decision boundary distance.

**Differential gene expression analysis**

122 Differential gene expression analysis between the clusters was performed using DESeq2<sup>29</sup> using the corrected gene counts. We performed one-versus-rest analyses to identify differentially expressed genes in one cluster compared to all others. We annotated genes as transcription factors or coding for cell surface proteins using public databases.  $36,37$ 

### **Aberration enrichment analysis**

 To test if aberrations occurred more in a cluster than in others we first removed aberrations found in only one cohort or which occurred in less than 1% of the samples. We also included high *MECOM* expression in the analysis (VST expression > 6, based on the tail of a *MECOM* expression density plot). We tested for enrichment per aberration by performing an one-sided Fisher exact test for one cluster versus all others and adjusted p-values using the Benjamini-Hochberg (BH) procedure. We considered aberrations with a false discovery ratio (FDR) < 0.05 enriched.

#### **Survival analysis**

 We performed survival analysis using right censored overall survival data by generating Kaplan Meier (KM) curves on BEAT and TCGA survival data, comparing different groups of patients with the log rank test. We also performed Cox-regression using BEAT, TARGET and TCGA survival data for different patient groups and included cohort, sex and age as co-variables to analyse hazard ratios.

#### **Expression based score**

142 We created cell type score to assess the differentiation arrest of AML samples, using the mean 143 expression of 30 marker genes for six haematological cells.<sup>38</sup> Additionally, we created immune phenotype scores for cytolytic infiltration and HLA I and HLA II antigen presenting cells using the mean expression 145 of marker genes.

# **Drug response analysis**

 To analyse drug response differences, we used ex-vivo drug response data of 331 BEAT<sup>3</sup> samples, quantified as area under the curve (AUC). We excluded drugs with less than 200 samples or missing data for any cluster, leaving 103 of the 123 drugs. We used a Kruskal-Wallis test for each drug with the AUC as response and clusters as groups to compare the average drug response per cluster.

Drugs with a significant difference (FDR<.05) were analysed with one-sided Wilcoxon tests to identify

clusters with low AUCs. Additionally, we performed a Kruskal-Wallis test for each drug with the ICC 2022

diagnosis as groups, to compare with clusters as groups.

 Multivariate linear models (LM) were evaluated per drug to test if clusters were sensitive to a drug when adjusted for cell type, with AUC as response and cluster membership (one-versus-rest) and the six cell type scores as explaining variables. Similarly, we fitted LMs but with cluster membership and ICC 2022 diagnoses as variables. We considered clusters sensitive to a drug if the cluster membership's FDR was below 0.05 and the LM coefficient was negative. All p-values were corrected using BH.

#### **Data Sharing Statement**

 The datasets generated and/or analysed during the current study are available from [www.github.com/jeppeseverens/AMLmap.](http://www.github.com/xxx/AMLMap)

#### **Code availability**

 All code used to generate results is available on reasonable request. The predictor is available from [www.github.com/jeppeseverens/AMLmapR](http://www.github.com/xxx/AMLMapR) as an R package.

**Results**

### **Multi-cohort AML gene expression compendium**

 We collected 1224 RNAseq samples from adult (BEAT, TARGET, TCGA, Leucegene, LUMC) and paediatric (TARGET) cohorts with corresponding genetic and clinical data (**Figure 1A**). We quantified gene expression with the same pipeline and corrected counts for cohort, sex and source tissue (**Supplemental Figure 1**). Sample classification by their genetic data according to the WHO (**Figure 1C**) and ICC was successful for 97% of the samples. In line with previous reports, frequencies of the AML subtypes were similar for the adult cohorts but different between paediatric and adult cohorts 177 (Supplemental Table 1), confirming that our dataset is representative of the AML landscape.<sup>40,5</sup>

# **Transcriptomics define 17 AML clusters**

 Next, we assigned AML cases to 17 transcriptional clusters using consensus clustering (**Figure Supplemental Figures 2 & 3).** We named the clusters based on genetic diagnoses (**Figure 1B, Supplemental Figure 4 & 5**). As expected, the distribution over the clusters was different for paediatric

182 and adult cohorts, exemplified by the large percentage of paediatric samples in the KMT2A<sup>T</sup> clusters 183 (26%), and adult samples in the NPM1<sup>T</sup> (93%) and AML-MRC<sup>T</sup> (94%) clusters (**Supplemental Table 1, Supplemental Figure 6**). However, samples of identical AML genetic subtypes from adult and paediatric cohorts clustered together, indicating that the 17 clusters capture differences in AML biology.

 We examined clustering robustness using the stability score (**Supplemental Figure 7**). Median 187 clustering stability was high (0.97-1.00), with AML-MRC(3)<sup>T</sup> showing the lowest stability. A correlation test revealed a significant but weak correlation (rho = 0.18, p-value<.001) between blast percentage and clustering robustness, but blast percentage varied greatly in clusters. tSNEs generated using different MVGs (**Supplemental Figure 8**) were stable from 500 to 2500 features. These results show that clustering was robust and only weakly influenced by blast percentage.

 We developed a transcriptional cluster predictor using uncorrected counts as input (accuracy = 0.90), demonstrating the persistence of expression patterns. The quality of the predictor was further improved (accuracy = 0.95) by including a reject option (10% rejected) (**Supplemental Figure 9**).

 Next, we tested for enrichment of mutations, fusions and cytogenetic aberrations (n=102) (**Figure 1E**, p-values and frequencies in **Supplemental Table 2**). Four transcriptomic clusters corresponded to 197 singular genetic AML subtypes: RUNX1::RUNX1T1<sup>T</sup> (*RUNX1::RUNX1T1*: 94%, FDR<.001), CBFB::MYH11<sup>T</sup>(*CBFB::MYH11*: 95%, FDR<.001), PML::RARA<sup>T</sup> (*PML::RARA*: 100%, FDR<.001), and 199 NUP98<sup>T</sup> (*NUP98::NSD1*: 45%, FDR<.001). Risk-stratification for survival based on transcriptional subtypes performed similarly to genetics (**Supplemental Figure 10 & 11**). We identified no enrichment for *BCR::ABL1* and *DEK::NUP214*, possibly due to their limited occurrence. For *KMT2A* rearrangements, *CEBPA* mutations, *NPM1* mutations, and AML-MRC, we found evidence that transcriptomics can refine subtyping, as described below.

#### **Transcriptome analysis identifies two** *KMT2A***-related clusters**

 The WHO classification defines a single *KMT2A*-rearranged subtype (*KMT2A*-r), while the ICC 207 recognises *KMT2A::MLLT3* and other *KMT2A* fusions as distinct.<sup>6,7</sup> We identified two *KMT2A* fusion 208 clusters. KMT2A(1)<sup>T</sup> was significantly enriched for *KMT2A::MLLT3* (31%, FDR<.001)*, KMT2A::MLLT10* (19%, FDR<.001) and any *KMT2A* fusion (67%, FDR<.001), while  $KMT2A(2)^{T}$  was enriched for *KMT2A::MLLT4* (67%, FDR<.001) and high *MECOM* expression (80%, FDR<.001) (**Figures 2A & B**).

211 Interestingly, we found cases with *NPM1* mutations and trisomy 8/8q localised in KMT2A(1)<sup>T</sup>, indicating

212 that these lead to *KMT2A* fusion-like gene expression.

213 The genes *LAMP5*, and *ADCY9* showed high expression in KMT2A(1)<sup>T</sup> and low expression in 214 KMT2A(2)<sup>T</sup> (Figure 2B), and all have been shown to contribute to AML pathogenesis<sup>41,42</sup>. Additionally, 215 the transcription factor (TF)  $ETV2$  was highly expressed in KMT2A(1)<sup>T</sup>, while the TF *ERG* displayed high 216 expression in KMT2A(2)<sup>T</sup>. The cell type scores revealed KMT2A(1)<sup>T</sup> to have a significantly higher 217 promonocyte-like score (FDR<.001), while KMT2A(2)<sup>T</sup> was more hematopoietic stem cell (HSC)-like 218 (FDR<.001) (**Figure 2B**, **Supplemental Figure 12**). FAB annotations showed similar results for 219 KMT2A(1)<sup>T</sup>, which had a high M5 (monocytic leukaemia) fraction (90%), while KMT2A(2)<sup>T</sup> was more 220 mixed (**Figure 2C**). Overall, we found that gene expression-based separation of *KMT2A*-r did not align 221 with the ICC 2022 classification.

222

# **The CEBPA<sup>T</sup>** 223 **cluster indicates a favourable prognosis**

224 As acknowledged in the ELN2022, patients with a *CEBPA* bZIP inframe mutation have a 225 favourable prognosis.<sup>8,43</sup> We identified a transcriptional CEBPA<sup>T</sup> cluster significantly enriched for mutated 226 *CEBPA* cases (72%, FDR<.001), with 42% of the samples having a *CEBPA* bZIP indel, either as single 227 mutation or combined with an N-terminal frameshift mutation (**Figure 3A & B**). The remaining samples 228 contained other mutations in the bZIP area or N-terminal region or had no detectable *CEBPA* mutation. 229 Of note, a single *CEBPA* bZIP indel case resided outside the CEBPA<sup>T</sup> cluster. This patient had an IDH-230 R132 mutation with a VAF=0.47, while the CEBPA bZIP in-frame mutation had a VAF=0.21. This finding 231 suggests that the *IDH*-R132 mutation dominates the expression pattern, placing this case in cluster AML-232 MRC(1)<sup>T</sup>. Conversely, all CEBPA<sup>T</sup> cluster patients showed similar favourable outcomes (log-rank test: p-233 value=.80), irrespective of whether the *CEBPA* bZIP inframe mutation was detected (**Figure 3C**). The 234 CEBPA<sup>T</sup> cluster thus marks patients with a favourable outcome regardless of *CEBPA* mutation detection, 235 which the CEBPA<sup>T</sup> expression profile can detect.

### 236 **Gene expression profiling identifies five transcriptional** *NPM1***-related clusters**

237 The 2022 WHO and ICC classifications include one subtype of *NPM1*-mutated AML.<sup>6,7</sup> However, 238 we identified five clusters enriched for mutated *NPM1* (**Figure 4**). We observed elevated expression of *HOXA3*, *HOXB5*, and *MEIS1* (**Figure 4A**), which has been earlier associated with *NPM1* mutations.<sup>44</sup> 239

240 Interestingly, *NPM1* mutation-lacking samples generally also exhibited high expression of these genes, 241 suggesting that there are alternative mishaps that disrupt these genes leading to *NPM1* mutated-like 242 AML.

243 **exhibited the highest percentage (95%, FDR**<.001) of *NPM1* mutated samples and 244 was significantly enriched for *IDH1*-R132 (25%, FDR<.001), *IDH2*-R140 (37%, FDR<.001), and *TET2*  (33%, FDR<.001) co-mutations (**Figure 4A**). NPM1(2)<sup>T</sup> 245 samples were enriched for *FLT3*-ITD mutations 246 (84%, FDR<.001), but *FLT3*-ITD was also enriched in NPM1(1)<sup>T</sup>, NPM1(3)<sup>T</sup> and NPM1(4)<sup>T</sup> (42-43%, all 247 FDR<.001). Additionally, NPM1(4)<sup>T</sup> and NPM1(5)<sup>T</sup> had a significantly lower variant allele frequency for 248 mutated *NPM1* (**Figure 4B**). We found two *NPM1*::*MLF1* cases in our compendium, which both clustered 249 in NPM1(3)<sup>T</sup>. *NPM1::MLF1* has been shown to localise in the cytoplasm<sup>45</sup>, like mutated *NPM1*, possibly 250 leading to a similar expression profile as *NPM1*-mutated cases.

251 Each of the *NPM1*-related clusters exhibited unique marker genes (**Figure 4A**). For instance, 252 FTO expression was high in NPM1(1)<sup>T</sup>. Additionally, *LYRM1*, *ADAM8*, and *DNAJC13* were elevated in 253 NPM1(2)<sup>T</sup>, NPM1(4)<sup>T</sup>, and NPM1(5)<sup>T</sup>, respectively. NPM1(3)<sup>T</sup> had a less distinct expression pattern, 254 suggesting a more heterogeneous cluster. Also, we observed differential expression of TFs (*RUNX1*, 255 PRDM16, SPI1)<sup>46,47</sup> – even in samples lacking the *NPM1* mutation – and TF expression aligned with cell 256 differentiation stages.

 $257$  NPM1(1)<sup>T</sup> and NPM1(2)<sup>T</sup> displayed a HSC-like expression pattern, NPM1(3)<sup>T</sup> was mixed, 258 whereas NPM1(4)<sup>T</sup> and NPM1(5)<sup>T</sup> were more differentiated (**Figure 4A, Supplemental Figure 12**). FAB 259 annotations showed additional differences, with  $NPM1(5)^T$  containing fewer M4 (myelomonocytic 260 leukaemia) but more M5 (monocytic leukaemia) cases than NPM1(4)<sup>T</sup> (Figure 4C & D). Using scores for 261 HLA I and HLA II antigen-presenting cells<sup>39</sup> we found NPM1(1)<sup>T</sup> to have significantly lower HLA I (FDR<.001) and HLA II (FDR<.001) scores than the other clusters (**Figure 4E & F**). NPM1(1)<sup>T</sup> and 263 NPM1(5)<sup>T</sup> patients were significantly older (FDR<.05), while NPM1(3)<sup>T</sup> patients were younger (FDR<.01) 264 (**Supplemental Figure 6F**). Our findings emphasise the existence of distinct *NPM1*-related subsets, 265 highlighting the limitations of relying solely on genetic classification.

# 266 **Gene expression profiling identifies five transcriptional AML-MRC-related clusters**

267 The ICC 2022 divides AML-MRC into three groups based on TP53 mutations, myelodysplasia-268 related gene mutations, and cytogenetic abnormalities.<sup>7</sup> Our study identified five gene expression-based

269 AML-MRC related clusters (**Figure 5**), with varying fractions of *TP53* mutations, MRC gene mutations, 270 and cytogenetic abnormalities.

 Despite sharing these mishaps, each cluster had unique characteristics (**Figure 5A)**. AML- $MRC(1)^T$  was characterised by  $IDH1-R132$  (49%, FDR<.001) and  $IDH2-R170$  (27%, FDR<.001) 273 mutations. A DNMT3A and *IDH1/2* mutated subtype has been reported<sup>5</sup>, but 41% of the AML-MRC(1)<sup>T</sup> 274 cases lacked *DNMT3A* mutations. AML-MRC(2)<sup>T</sup>, AML-MRC(3)<sup>T</sup>, and AML-MRC(4)<sup>T</sup> were all enriched (FDR<.001) for *TP53* mutations, cytogenetic abnormalities and high *MECOM* expression, and AML-276 MRC(3)<sup>T</sup> also contained a large fraction of mutated MRC genes (65%, FDR<0.001). AML-MRC(5)<sup>T</sup> stood out with the highest fraction of mutated MRC genes cases (81%, FDR<.001) and the lowest fraction of *TP53* mutations (6%) and cytogenetic abnormalities (34%).

279 We found marker genes for all clusters (**Figure 5A**). For instance, high S*RSF12* marked AML-280 MRC(1)<sup>T</sup>, and LINC00865 marked AML-MRC(5)<sup>T</sup>. AML-MRC(2)<sup>T</sup> presented high glycophorin genes and 281 UROD expression, suggesting an association with acute erythroid leukaemia.<sup>48–50</sup> Distinct cell 282 differentiation scores further highlighted differences (**Figure 5A-C, Supplemental Figure 12)**. For 283 example, AML-MRC $(1)^T$  showed high progenitor-like scores, with 65% M1 (minimal maturation) cases, 284 and AML-MRC $(3)^T$  showed a more differentiated pattern, with 54% M2 (significant maturation) cases. 285 AML-MRC(2)<sup>T</sup> was the only cluster with M6 (erythroid leukaemia) – in line with high expression of 286 erythrocyte cell markers – and M7 (megakaryocytic leukaemia) cases. Additionally, high cytolytic cell 287 infiltration has been reported for AML-MRC cases.<sup>39</sup> Using the same score (**Figure 5D**) we found that the 288 cytolytic infiltration was significantly (FDR<.05) lower for AML-MRC(1)<sup>T</sup> and higher for AML-MRC(2)<sup>T</sup> 289 compared to the other AML-MRC clusters. Our results demonstrate that different AML-MRC 290 transcriptomic clusters can be identified, showing genetic enrichments that do not necessarily align with 291 the ICC 2022 classification.

### 292 **AML clusters exhibit cell type-independent differences in ex-vivo drug responses**

 Finally, we assessed the drug sensitivity of the transcriptional AML subtypes. Using ex-vivo drug response data, we discovered 101 drug-cluster combinations with significantly lower resistance (FDR<.05), of which 21 combinations remained statistically significant (FDR<.05) when adjusting for cell differentiation status (**Figure 6**, **Supplemental Figure 13, Supplemental Table 3**).

 The ex-vivo drug responses between *NPM1*-related clusters were often divergent, exemplified by 298 venetoclax and selumetinib (Figure 6A,B). NPM1(1)<sup>T</sup>, NPM1(2)<sup>T</sup> and NPM1(3)<sup>T</sup> mostly responded 299 positively to tyrosine kinase inhibitors and CDK kinase inhibitors. NPM1(4)<sup>T</sup> and NPM1(5)<sup>T</sup> samples were more sensitive to PI3K and MAPK kinase inhibitors. We also found drugs where only one cluster was 301 responsive, exemplified by axitinib for NPM1(4)<sup>T</sup> where this effect remained significant (FDR<.05) when controlled for cell type scores (**Figure 6C**).

 Several drugs demonstrated favourable ex-vivo responses in KMT2A(1)<sup>T</sup> compared to the other 304 clusters, exemplified by idelalisib. For KMT2A(2)<sup>T</sup> we found no significant responsive drugs, but testing was limited due to small cluster size. For the AML-MRC clusters, most drugs showed strong resistance. 306 Still, specific drugs were more effective for AML-MRC(1)<sup>T</sup>, AML-MRC(4)<sup>T</sup>, and AML-MRC(5)<sup>T</sup> (Figure 6A, **B**), suggesting potential for targeted treatments in this diverse, high-risk patient group.

 Next, we examined if transcriptional clusters provide insights beyond genetic classifications. Comparing the AUCs of each drug between groups, we found 71 drugs with significantly different (FDR<.05) median AUCs between the clusters, while only 21 drugs were significantly different between ICC 2022 classes (**Figure 6D**). Additionally, 57 of the 101 cluster-drug combinations remained significant (FDR<.05) when cluster membership and ICC 2022 diagnosis were included in a LM, suggesting that the transcriptional clusters offer information beyond genetic classification.

 Overall, our findings offer novel opportunities for targeted therapy in AML. We observed effective drug responses even after adjusting for differentiation status, possibly allowing gene expression-based subtypes to guide treatment strategies.

# **Discussion**

 This study presents an overview of transcriptomics in AML and provides a framework for transcriptional subtyping. We integrate multiple cohorts to identify 17 robust transcriptional subtypes that subclassify ~75% of our datasets' patients. We make the harmonised data and a cluster predictor publicly available, facilitating future research.

For the CEBPA<sup>T</sup> cluster, we show that patients without a detected *CEBPA* bZIP indel mutation still have similar favourable survival. Patients without the canonical *CEBPA* mutation in the CEBPA<sup>T</sup> cluster could be explained by undetected mutations, given the complexities of CEBPA sequencing. Also,

325 CEBPA hypermethylation has been described to lead to a similar expression profile.<sup>51</sup> The use of the CEBPA<sup>T</sup> gene signature for risk stratification could be a relevant alternative to detect these favourable-outcome patients.

328 KMT2A(1)<sup>T</sup> mainly featured *KMT2A* with the fusion partners *MLLT3*, *MLLT10* and *MLLT1* – all TFs in the super elongation complex whose perturbation leads to disrupted hematopoietic lineage 330 commitment.<sup>52</sup> In contrast, KMT2A(2)<sup>T</sup> featured *KMT2A::MLLT4*, which is thought to cause leukaemia by promoting self-association<sup>53</sup> . Interestingly, *MLLT3*, *MLLT10* and *MLLT1* all fuse a specific region of 332 *KMT2A*, but *MLLT4* shows less specificity.<sup>54</sup> Collectively, these results suggest that two types of oncogenic mechanisms involving *KMT2A* fusions exist that may be marked with unique gene expression patterns.

 We identified five *NPM1*-related clusters, further underpinning findings of transcriptional 336 heterogeneity among *NPM1*-mutated patients<sup>15,16,55</sup>, but also providing additional insight into co- mutations and detailed subtypes. We observed several samples from *NPM1*-related clusters that lacked the *NPM1* mutation. Several rare *NPM1* fusions, like *NPM1::MLF1,* have been described to lead to 339 cytoplasmic localisation of NPM1, comparable to the canonical NPM1 frameshift.<sup>45,56</sup> These non- canonical mishaps could lead to a *NPM1*-mutated-like presentation and similarities in survival and drug 341 response should be explored. Additionally, NPM1(1)<sup>T</sup> was mutually exclusive enriched for *IDH1/2* and *TET2* co-mutations. *IDH1/2* mutations lead to an aberrant alpha-ketoglutarate metabolism and are 343 functionally complementary to TET2 loss-of-function mutations . While NPM1(1)<sup>T</sup> and NPM1(5)<sup>T</sup> show significant enrichments for *TET2*, only NPM1(1)<sup>T</sup> shows this mutual exclusivity with *IDH1/2*. This suggests 345 that only NPM1(1)<sup>T</sup> is driven by aberrant alpha-ketoglutarate metabolism, which should be further studied using metabolomics.

 Similarly, cytogenetic abnormalities, AML-MRC mutations and high MECOM expression were found in all AML-MRC clusters, but lead to different gene expression. A possible explanation could be clonal architecture and the differentiation state of the cell acquiring the leukemic aberration, both known 350 to influence the biology of the resultant leukaemia.<sup>58,59</sup> To our knowledge, we are the first to show different gene expression-based subgroups in AML-MRC, with divergent drug responses. Accurate identification of these clusters requires gene expression analysis, showing the relevance of our work.

 We found no additional survival differences between other clusters. However, data availability limited the survival analysis, and different treatment protocols across studies could have led to

 confoundment. Survival differences between transcriptional subtypes should thus be further explored in one large cohort. However, we did find marked differences in drug responses between the clusters. Ideally, new studies should test in-patient efficacy of drugs with good ex-vivo responses in transcriptional subtypes. Furthermore, transcriptional subtyping could aid AML specialists in the highly complex field of clinical care and lead to multidisciplinary tailored-based treatment advice.<sup>60</sup>

 In conclusion, the transcriptional subtypes reveal heterogeneity in AML not captured by genetic classification. Integration of transcriptomics into AML research and diagnostics could improve disease understanding and lead to more treatment options.

#### **Acknowledgements**

This project was funded by a strategic investment of the Leiden University Medical Center, embedded

within the Leiden Oncology Center, and executed within the Leiden Center for Computational Oncology.

EvdA was funded by a personal grant from the Dutch Research Council (NWO; VENI: 09150161810095).

 The funding bodies had no role in the study design, the collection, analysis, and interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication.

#### **Author Contributions**

 M.J.R., M.G., and E.B.A. conceived and designed the project; E.B.A. acquired funding; E.B.A. performed project administration; M.G., E.B.A., H.V., R.R.B., C.J.M.H., P.B. performed oversight and management of resources (data generation, collection, transfer, infrastructure, data processing); J.F.S. performed computational and statistical analyses; J.F.S., E.B.A., M.G., E.O.K., E.S.-L. performed analyses and interpretation; J.F.S. performed and structured data visualisation; M.J.R., M.G. and E.B.A. provided supervision and scientific direction; J.F.S. wrote the manuscript; and all authors critically reviewed the manuscript and figures.

#### **Disclosure of interest**

The authors declare no competing financial interests.

# **References**

1. The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.03.29.23287896;](https://doi.org/10.1101/2023.03.29.23287896) this version posted December 8, 2023. The copyright holder for this

- It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .
- Novo Acute Myeloid Leukemia. *N. Engl. J. Med.* 2013;368(22):2059–2074.
- 2. Farrar JE, Schuback HL, Ries RE, et al. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. *Cancer Res.* 2016;76(8):2197–2205.
- 3. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. *Nat. 2018 5627728*. 2018;562(7728):526–531.
- 4. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N. Engl. J. Med.* 2016;374(23):2209–2209.
- 5. Tazi Y, Arango-Ossa JE, Zhou Y, et al. Unified classification and risk-stratification in Acute Myeloid Leukemia. *Nat. Commun.* 2022;13(1):4622.
- 6. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*. 2022;36(7):1703–1719.
- 7. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200–1228.
- 8. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*. 2022;140(12):1345–1377.
- 9. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. *Nat. Med.* 2020;26(12):1852–1858.
- 10. Valk PJM, Verhaak RGW, Beijen MA, et al. Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia. *N. Engl. J. Med.* 2004;350(16):1617–1628.
- 11. Lavallée V-P, Baccelli I, Krosl J, et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. *Nat. Genet.* 2015;47(9):1030–1037.
- 12. Mou T, Pawitan Y, Stahl M, et al. The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia. *Am. J. Hematol.* 2021;96(5):580–588.
- 13. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, et al. Double CEBPA mutations, but not
- single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood*. 2009;113(13):3088–
- 3091.
- 14. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.
- *Blood*. 2011;117(8):2469–2475.
- 15. Mer AS, Heath EM, Madani Tonekaboni SA, et al. Biological and therapeutic implications of a unique subtype of NPM1 mutated AML. *Nat. Commun.* 2021;12(1):1054.
- 16. Cheng W-Y, Li J-F, Zhu Y-M, et al. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. *Proc. Natl. Acad. Sci.*

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.03.29.23287896;](https://doi.org/10.1101/2023.03.29.23287896) this version posted December 8, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



- 36. Lambert SA, Jolma A, Campitelli LF, et al. The Human Transcription Factors. *Cell*.
- 2018;172(4):650–665.
- 37. Bausch-Fluck D, Hofmann A, Bock T, et al. A Mass Spectrometric-Derived Cell Surface Protein Atlas. *PLOS ONE*. 2015;10(4):e0121314.
- 38. van Galen P, Hovestadt V, Wadsworth II MH, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. *Cell*. 2019;176(6):1265-1281.e24.
- 39. Dufva O, Pölönen P, Brück O, et al. Immunogenomic Landscape of Hematological Malignancies. *Cancer Cell*. 2020;38(3):380-399.e13.
- 40. Patel JP, Gönen M, Figueroa ME, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. *N. Engl. J. Med.* 2012;366(12):1079–1089.
- 41. Gracia-Maldonado G, Clark J, Mulloy JC, Kumar AR. LAMP5 a Novel Target of MLL-Fusion Proteins Is Required for the Propagation of Leukemia. *Blood*. 2016;128(22):1512.
- 42. Milan T, Celton M, Lagacé K, et al. Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis. *Haematologica*. 2022;107(1):86–99.
- 43. Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. *Blood Adv.* 2022;6(1):238–247.
- 44. Brunetti L, Gundry MC, Sorcini D, et al. Mutant NPM1 maintains the leukemic state through HOX expression. *Cancer Cell*. 2018;34(3):499-512.e9.
- 45. Falini B, Bigerna B, Pucciarini A, et al. Aberrant subcellular expression of nucleophosmin and NPM- MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML. *Leukemia*. 2006;20(2):368–371.
- 46. Aguilo F, Avagyan S, Labar A, et al. Prdm16 is a physiologic regulator of hematopoietic stem cells. *Blood*. 2011;117(19):5057.
- 47. Imperato MR, Cauchy P, Obier N, Bonifer C. The RUNX1–PU.1 axis in the control of hematopoiesis. *Int. J. Hematol.* 2015;101(4):319–329.
- 48. Hollox EJ, Louzada S. Genetic variation of glycophorins and infectious disease. *Immunogenetics*. 2022;
- 49. Greaves MF, Sieff C, Edwards PAW. Monoclonal Antiglycophorin as a Probe for Erythroleukemias. *Blood*. 1983;61(4):645–651.
- 50. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human leukaemia cell line K562. *Nature*. 1979;278(5702):364–365.
- 51. Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM, et al. Characterization of
- CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
- *Haematologica*. 2011;96(3):384–392.
- 52. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. *Nat. Rev. Cancer*. 2010;10(10):721–728.
- 53. Liedtke M, Ayton PM, Somervaille TCP, Smith KS, Cleary ML. Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. *Blood*. 2010;116(1):63–70.
- 54. Meyer C, Larghero P, Almeida Lopes B, et al. The KMT2A recombinome of acute leukemias in

2023. *Leukemia*. 2023;37(5):988–1005.

- 55. Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O. A distinct immunophenotype
- identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome. *Am. J. Hematol.* 2018;93(4):504–510.
- 56. Martelli MP, Rossi R, Venanzi A, et al. Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. *Blood*. 2021;138(25):2696–2701.
- 57. Figueroa ME, Wahab OA, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a
- hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*. 2010;18(6):553–567.
- 58. Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. *Nat. Commun.* 2020;11(1):5327.
- 59. Krivtsov AV, Figueroa ME, Sinha AU, et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. *Leukemia*. 2013;27(4):852–860.
- 60. Willemsen AECAB, Krausz S, Ligtenberg MJL, et al. Molecular tumour boards and molecular
- diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
- *Br. J. Cancer*. 2019;121(1):34–36.

# **Figure legends**

#### **Figure 1: Transcriptomic analysis further stratifies AML.**

 **A)** Flowchart of the used data and methods. **B)** Sankey plot showing the assignment of WHO 2022 diagnoses over the identified clusters. **C)** tSNE visualisation of the gene expression of patient samples. Each dot represents a patient. The samples are coloured according to the WHO 2022 subtyping of AML. **D)** The same tSNE visualisation as in **C**, but samples are coloured according to the 17 clusters. **E)** Dot plots that show enriched aberrations in the 17 clusters. The dots are coloured according to the adjusted p-value. The dots are sized according to the sample fraction with the aberration in the cluster. The x-axis shows the aberrations, and the y-axis shows the clusters. We only visualised enriched aberrations that occurred in at least 10% of the patients in a cluster.

#### **Figure 2: Transcriptome analysis identifies two** *KMT2A***-related clusters.**

 **A)** tSNE visualisation of patient samples, coloured according to *KMT2A*-fusion or *NPM1* mutation and trisomy 8. **B)** Waterfall plot of aberrations in the KMT2A clusters, including the percentage of samples with the aberration. The plot is combined with heatmaps showing the expression of marker genes and cell type scores. The columns are samples, which are split according to transcriptional clusters. **C)** Fraction of FAB annotations per cluster. HSC = hematopoietic stem cells, Prog. = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. = monocytes, cDC = conventional dendritic cells

# **Figure 3: The CEBPA<sup>T</sup> cluster indicates a favourable prognosis.**

542  $\bullet$  **A)** Waterfall plot and gene expression heatmap of all samples in the CEBPA<sup>T</sup> cluster and samples with a 543 CEBPA mutation located outside the CEBPA<sup>T</sup> cluster. **B)** *tSNE* visualisation of patient samples, coloured according to the type of *CEBPA* mutation. For samples with multiple *CEBPA* mutations, we used the ordering as in **A** to decide which mutation to display. **C)** Kaplan-Meier curve of the survival of BEAT and 546 TCGA patients in and outside the CEBPA $<sup>T</sup>$  cluster.</sup>

### **Figure 4: Gene expression profiling identifies five transcriptional** *NPM1***-related clusters.**

 **A)** Waterfall plot of aberrations in the *NPM1*-related clusters, including the percentage of samples with the aberration. The plot is combined with heatmaps showing the expression of marker genes and cell

 type scores. The columns are samples, which are split according to transcriptional clusters. **B)** Boxplot showing the scaled variant allele frequency (VAF) of mutated *NPM1* from the BEAT, Leucegene, and LUMC cohorts. The VAF was scaled per gene and study to allow for a combined analysis. We used a two-sided Wilcoxon test to test for statistical differences and Benjamini-Hochberg to adjust p-values for multiple testing. **C)** tSNE visualisation of patient samples, coloured according to the FAB annotation. Only *NPM1*-related clusters are coloured; the rest are in grey. **D)** Fraction of FAB annotations per cluster. **E)**  and **F)** show boxplots of HLA I and HLA II antigen presenting cell scores, respectively. Tests were 558 performed as in **B**, but were only done between the two KMT2A<sup>T</sup>, the five NPM1<sup>T</sup> and the five AML-MRC<sup>T</sup> clusters. FDR values: \* < 0.05, \*\* < 0.01, \*\*\* < 0.005, \*\*\*\* < 0.001. HSC = hematopoietic stem cells, Prog. = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. = monocytes, cDC = conventional dendritic cells, VAF = variant allele frequency

#### **Figure 5: Gene expression profiling identifies five transcriptional AML-MRC-related clusters**

 **A)** Waterfall plot of aberrations in the AML-MRC-related clusters, including the percentage of samples with the aberration. We did not plot enriched individual large chromosomal mishaps. The plot is combined with heatmaps showing the expression of marker genes and cell type scores. The columns are samples, which are split according to transcriptional clusters. MRC genes are *ASXL1*, *BCOR*, *EZH2*, *RUNX1*, *SF3B1*, *SRSF2*, *STAG2*, *U2AF1*, or *ZRSR2*. Cytogenetic abnormalities are the ICC 2022 aberrations that define AML-MRC with cytogenetic abnormalities. **B)** tSNE visualisation of patient samples, coloured according to the FAB annotation. Only AML-MRC clusters samples are coloured are coloured; the rest are in grey. **C)** Fraction of FAB annotations per cluster. **D)** Boxplots of cytolytic cell score per cluster. We used a two-sided Wilcoxon test to test for statistical differences and Benjamini-Hochberg to adjust p-573 values for multiple testing. Tests were performed only between the two KMT2A<sup>T</sup>, the five NPM1<sup>T</sup> and the 574 five AML-MRC<sup>T</sup> clusters. FDR values:  $* < 0.05$ ,  $** < 0.01$ ,  $*** < 0.005$ ,  $*** < 0.001$ . HSC = hematopoietic stem cells, Prog. = progenitor, GMP = granulocyte-monocyte progenitor, Prom. = promonocytes, Mono. = monocytes, cDC = conventional dendritic cells

# **Figure 6: AML clusters exhibit cell type-independent differences in ex-vivo drug responses**

 **A)** Heatmap coloured according to the median scaled area under the curve (AUC) of the ex-vivo drug response per drug and cluster. On the left is the drug name, and on the right is the drug family. A green

 colour indicates a lower median AUC for the drug for the samples in the cluster compared to the other clusters, indicating a strong drug response. Red indicates a higher median AUC, meaning a weak drug response. **B)** Boxplots showing ex-vivo drug responses for a selection of drugs. We performed significance testing using a two-sided Wilcoxon test. FDR values: \* < 0.05, \*\* < 0.01, \*\*\* < 0.05, \*\*\*\* < 0.001. **C)** Plots of the multivariate linear models with cluster membership and the six cell type scores as independent variables and AUC as the dependent variable. On the x-axis, the coefficient of the variables in the models is shown, and the y-axis shows the -log10 of the p-value for each variable. The shown p- values are not corrected and are for visualisation to indicate variable importance in the multivariate model. The corrected p-values of the cluster membership variable are shown in **Supplemental Table 3.** The red line indicates a p-value of 0.05. **D)** Barplots of the top 40 drugs with highest corrected p-values for Kruskal- Wallis tests between ex-vivo drug response and clusters or ICC 2022 diagnosis to test if there were significant differences in the median AUCs. All p-values were corrected with Benjamini-Hochberg.



# **A Figure 2 KMT2A fusions & NPM1 + trisomy 8/8q**





- **O** KMT2A::ELL
- KMT2A::MLLT1
- O KMT2A::MLLT10
- O KMT2A::MLLT3
- O KMT2A::MLLT4
- KMT2A::MLLT6
- O KMT2A::SEPT6
- O KMT2A::SEPT9
- O No KMT2A
- O NPM1 + trisomy 8/8q
- O Other KMT2A











